• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人血清可对表皮生长因子受体（EGFR）靶向药物抑制鳞状癌细胞生长的作用产生供体特异性拮抗。

Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth.

作者信息

Kamashev Dmitry, Sorokin Maksim, Kochergina Irina, Drobyshev Aleksey, Vladimirova Uliana, Zolotovskaia Marianna, Vorotnikov Igor, Shaban Nina, Raevskiy Mikhail, Kuzmin Denis, Buzdin Anton

机构信息

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Miklukho-Maklaya St., Moscow 117997, Russia.

World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, 8-2, Trubetskaya St., Moscow 119992, Russia.

出版信息

Heliyon. 2021 Mar 11;7(3):e06394. doi: 10.1016/j.heliyon.2021.e06394. eCollection 2021 Mar.

DOI:10.1016/j.heliyon.2021.e06394
PMID:33748471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7966997/
Abstract

Many patients fail to respond to EGFR-targeted therapeutics, and personalized diagnostics is needed to identify putative responders. We investigated 1630 colorectal and lung squamous carcinomas and 1357 normal lung and colon samples and observed huge variation in EGFR pathway activation in both cancerous and healthy tissues, irrespectively on gene mutation status. We investigated whether human blood serum can affect squamous carcinoma cell growth and EGFR drug response. We demonstrate that human serum antagonizes the effects of EGFR-targeted drugs erlotinib and cetuximab on A431 squamous carcinoma cells by increasing IC50 by about 2- and 20-fold, respectively. The effects on clonogenicity varied significantly across the individual serum samples in every experiment, with up to 100% differences. EGF concentration could explain many effects of blood serum samples, and EGFR ligands-depleted serum showed lesser effect on drug sensitivity.

摘要

许多患者对表皮生长因子受体（EGFR）靶向治疗药物没有反应，因此需要个性化诊断来识别可能的反应者。我们研究了1630例结直肠癌和肺鳞癌以及1357例正常肺和结肠样本，观察到无论基因突变状态如何，癌组织和健康组织中EGFR通路激活都存在巨大差异。我们研究了人血清是否会影响肺鳞癌细胞的生长和EGFR药物反应。我们证明，人血清通过将半数抑制浓度（IC50）分别提高约2倍和20倍，拮抗EGFR靶向药物厄洛替尼和西妥昔单抗对A431肺鳞癌细胞的作用。在每个实验中，各个血清样本对克隆形成能力的影响差异显著，差异高达100%。表皮生长因子（EGF）浓度可以解释血清样本的许多作用，而不含EGFR配体的血清对药物敏感性的影响较小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/7be6daf58c9a/figs6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/22c5129333c7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/9a1b61dcba2c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/180657a0f377/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/bb11fdff19e5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/7e832cad04de/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/4dda7321b1d6/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/fa95fdaecb49/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/a5ec6a5927a8/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/8cda6a7f0666/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/b4573d7c3d63/figs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/350ddefa2b8d/figs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/16ac13a208e2/figs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/5f3462a0052b/figs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/26ace23af5c4/figs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/7be6daf58c9a/figs6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/22c5129333c7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/9a1b61dcba2c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/180657a0f377/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/bb11fdff19e5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/7e832cad04de/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/4dda7321b1d6/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/fa95fdaecb49/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/a5ec6a5927a8/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/8cda6a7f0666/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/b4573d7c3d63/figs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/350ddefa2b8d/figs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/16ac13a208e2/figs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/5f3462a0052b/figs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/26ace23af5c4/figs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f34/7966997/7be6daf58c9a/figs6.jpg

相似文献

1
Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth.人血清可对表皮生长因子受体（EGFR）靶向药物抑制鳞状癌细胞生长的作用产生供体特异性拮抗。
Heliyon. 2021 Mar 11;7(3):e06394. doi: 10.1016/j.heliyon.2021.e06394. eCollection 2021 Mar.
2
Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways.人血清可通过重新激活 MAPK 和 EGFR 通路减弱表皮生长因子受体靶向抑制剂对鳞癌细胞生长的抑制作用。
Cells. 2023 Aug 8;12(16):2022. doi: 10.3390/cells12162022.
3
The ErbB/HER family of protein-tyrosine kinases and cancer.表皮生长因子受体（ErbB）/HER 家族蛋白酪氨酸激酶与癌症。
Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20.
4
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.厄洛替尼联合西妥昔单抗与非小细胞肺癌（包括鳞状细胞癌）和野生型 EGFR 或耐药突变患者的活性相关。
Mol Cancer Ther. 2013 Oct;12(10):2167-75. doi: 10.1158/1535-7163.MCT-12-1208. Epub 2013 Aug 20.
5
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.表皮生长因子受体（EGFR）配体 Amphiregulin 和 Epiregulin 的交叉抑制以及成纤维细胞生长因子受体 3（FGFR3）信号的去抑制导致野生型 KRAS 肿瘤细胞对西妥昔单抗产生耐药性。
Br J Cancer. 2012 Apr 10;106(8):1406-14. doi: 10.1038/bjc.2012.103.
6
The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.缺氧肿瘤微环境与对表皮生长因子受体（EGFR）抑制剂的耐药性：西妥昔单抗敏感的头颈部鳞状细胞癌细胞系的临床前研究
BMC Res Notes. 2015 Jun 2;8:203. doi: 10.1186/s13104-015-1197-6.
7
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.双调蛋白的自分泌产生预示着表皮生长因子受体野生型癌症对吉非替尼和西妥昔单抗均敏感。
Clin Cancer Res. 2008 Nov 1;14(21):6963-73. doi: 10.1158/1078-0432.CCR-08-0957.
8
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.干扰素/STAT1 和神经调节素信号通路是西妥昔单抗（爱必妥®）在 KRAS 野生型鳞状细胞癌中疗效的探索性生物标志物：基于通路的全基因组微阵列数据分析来自西妥昔单抗适应的肿瘤细胞系模型。
Int J Oncol. 2011 Dec;39(6):1455-79. doi: 10.3892/ijo.2011.1155. Epub 2011 Aug 9.
9
Cy5.5 conjugated anti-epidermal growth factor receptor monoclonal antibodyCy5.5偶联的抗表皮生长因子受体单克隆抗体
10
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).非小细胞肺癌（NSCLC）中的表皮生长因子受体（EGFR）靶向治疗
Rev Recent Clin Trials. 2006 Jan;1(1):1-13. doi: 10.2174/157488706775246157.

引用本文的文献

1
Lapatinib-induced enhancement of mitochondrial respiration in HER2-positive SK-BR-3 cells: mechanism revealed by analysis of proteomic but not transcriptomic data.拉帕替尼诱导HER2阳性SK-BR-3细胞线粒体呼吸增强：通过蛋白质组学而非转录组学数据分析揭示机制
Front Mol Biosci. 2024 Sep 30;11:1470496. doi: 10.3389/fmolb.2024.1470496. eCollection 2024.
2
Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications.靶向 EGFR 的抑制剂：结构、生物学、生物标志物和临床应用。
Cells. 2023 Dec 25;13(1):47. doi: 10.3390/cells13010047.
3
Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways.

本文引用的文献

1
Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.非小细胞肺癌中的脑膜转移：有无驱动基因突变的 NSCLC 的最佳全身治疗策略。
Curr Treat Options Oncol. 2020 Jul 28;21(9):72. doi: 10.1007/s11864-020-00759-3.
2
Mechanisms of resistance to osimertinib.对奥希替尼的耐药机制。
J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30.
3
Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.
人血清可通过重新激活 MAPK 和 EGFR 通路减弱表皮生长因子受体靶向抑制剂对鳞癌细胞生长的抑制作用。
Cells. 2023 Aug 8;12(16):2022. doi: 10.3390/cells12162022.
4
Transcriptome-Based Traits of Radioresistant Sublines of Non-Small Cell Lung Cancer Cells.基于转录组的非小细胞肺癌细胞放射抗拒亚系的特征。
Int J Mol Sci. 2023 Feb 3;24(3):3042. doi: 10.3390/ijms24033042.
5
Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition.人血清抑制导管癌细胞BT474生长并调节HER2抑制作用。
Biomedicines. 2022 Aug 8;10(8):1914. doi: 10.3390/biomedicines10081914.
6
Transcriptomic Portraits and Molecular Pathway Activation Features of Adult Spinal Intramedullary Astrocytomas.成人脊髓髓内星形细胞瘤的转录组图谱及分子通路激活特征
Front Oncol. 2022 Mar 21;12:837570. doi: 10.3389/fonc.2022.837570. eCollection 2022.
7
RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples.福尔马林固定石蜡包埋肿瘤组织块的RNA测序数据可用于可靠估计个体生物样本中的肿瘤突变负荷。
Front Oncol. 2021 Sep 28;11:732644. doi: 10.3389/fonc.2021.732644. eCollection 2021.
8
Algorithmically Deduced Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas.通过算法推导的分子通路是人类胶质瘤的有效分级和生存生物标志物。
Cancers (Basel). 2021 Aug 16;13(16):4117. doi: 10.3390/cancers13164117.
表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌的临床预测因素：来自印度的真实世界多中心队列分析。
Curr Probl Cancer. 2020 Jun;44(3):100570. doi: 10.1016/j.currproblcancer.2020.100570. Epub 2020 Mar 20.
4
Developing effective combination therapy for pancreatic cancer: An overview.开发胰腺癌有效联合治疗方法：概述。
Pharmacol Res. 2020 May;155:104740. doi: 10.1016/j.phrs.2020.104740. Epub 2020 Mar 2.
5
Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma.肿瘤内异质性和基因表达的纵向变化预测新诊断和复发性胶质母细胞瘤的差异药物敏感性
Cancers (Basel). 2020 Feb 24;12(2):520. doi: 10.3390/cancers12020520.
6
RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer.RNA 测序谱和与胃癌对 ramucirumab 反应相关的诊断特征。
Cold Spring Harb Mol Case Stud. 2020 Apr 1;6(2). doi: 10.1101/mcs.a004945. Print 2020 Apr.
7
Mutation Enrichment and Transcriptomic Activation Signatures of 419 Molecular Pathways in Cancer.癌症中419条分子通路的突变富集与转录组激活特征
Cancers (Basel). 2020 Jan 22;12(2):271. doi: 10.3390/cancers12020271.
8
Quantitation of Molecular Pathway Activation Using RNA Sequencing Data.利用RNA测序数据对分子通路激活进行定量分析。
Methods Mol Biol. 2020;2063:189-206. doi: 10.1007/978-1-0716-0138-9_15.
9
RNA sequencing for research and diagnostics in clinical oncology.临床肿瘤学中的研究和诊断用 RNA 测序。
Semin Cancer Biol. 2020 Feb;60:311-323. doi: 10.1016/j.semcancer.2019.07.010. Epub 2019 Aug 11.
10
Evaluation of the Physicochemical and Biological Stability of Cetuximab under Various Stress Condition.评价西妥昔单抗在各种应激条件下的物理化学和生物学稳定性。
J Pharm Pharm Sci. 2019;22(1):171-190. doi: 10.18433/jpps30427.